10 BioMarin Pharmaceutical Analyst Ratings, Earnings, Dividends and Insider Trades | $BMRN | NASDAQ:BMRN | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact BioMarin Pharmaceutical Company Profile (NASDAQ:BMRN) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for BioMarin Pharmaceutical (NASDAQ:BMRN) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 9 Hold Rating(s), 10 Buy Rating(s)Consensus Rating:Buy (Score: 2.53)Consensus Price Target: $80.19 (3.82% upside) Analysts' Ratings History for BioMarin Pharmaceutical (NASDAQ:BMRN) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/27/2014ZacksReiterated RatingNeutral -> Neutral$87.00View 2/19/2014BarclaysBoost Price TargetEqual Weight$73.00 -> $76.00View 2/19/2014Jefferies GroupReiterated RatingBuy$87.00View 2/19/2014Citigroup Inc.Boost Price Target$79.00 -> $90.00View 1/14/2014Deutsche BankBoost Price TargetBuy$75.00 -> $85.00View 1/10/2014BarclaysDowngradeOverweight -> Equal Weight$75.00 -> $73.00View 1/8/2014NomuraInitiated CoverageNeutral$75.00View 1/3/2014ZacksReiterated RatingNeutral -> Neutral$73.00View 11/29/2013TheStreetUpgradeSell -> HoldView 11/26/2013Piper JaffrayInitiated CoverageOverweight$87.00View 11/20/2013BarclaysReiterated RatingBuy$75.00View 11/19/2013Wells Fargo & Co.Reiterated RatingPositiveView 10/28/2013ZacksReiterated RatingNeutral -> Neutral$70.00View 10/25/2013WedbushReiterated RatingHold$88.00View 10/25/2013BarclaysBoost Price TargetOverweight$70.00 -> $75.00View 9/27/2013Wells Fargo & Co.Reiterated RatingMarket PerformView 9/20/2013WedbushReiterated RatingHold$88.00View 9/18/2013William BlairReiterated RatingHold$88.00View 9/18/2013RBC CapitalReiterated RatingBuy$77.00View 9/18/2013Stifel NicolausDowngradeBuy -> Hold$70.00View 9/16/2013Bank of AmericaReiterated RatingBuyView 9/6/2013ZacksReiterated RatingNeutral -> Neutral$74.00View 9/5/2013Canaccord GenuitySet Price TargetBuy$71.00 -> $85.00View 7/29/2013ZacksReiterated RatingNeutral -> Neutral$67.00View 7/26/2013Goldman SachsReiterated RatingBuy$76.00View 7/26/2013UBS AGBoost Price Target$67.00View 7/26/2013Stifel NicolausBoost Price TargetBuy$67.00 -> $70.00View 7/4/2013ZacksReiterated RatingNeutral -> Neutral$62.00View 6/3/2013Leerink SwannReiterated RatingOutperform -> PositiveView 6/3/2013Deutsche BankUpgradeHold -> Buy$75.00View 5/31/2013WedbushBoost Price TargetHold$62.00 -> $63.00View 5/31/2013Credit SuisseInitiated CoverageNeutral$68.00View 5/31/2013Citigroup Inc.Set Price Target$72.00 -> $79.00View 5/16/2013WedbushBoost Price TargetNeutral$54.00 -> $62.00View 5/13/2013Deutsche BankBoost Price TargetHold$59.00 -> $75.00View 5/7/2013Goldman SachsInitiated CoverageBuyView 4/30/2013ZacksReiterated RatingNeutral -> Neutral$68.00View 4/26/2013RBC CapitalBoost Price TargetOutperform$64.00 -> $66.00View 4/26/2013Jefferies GroupBoost Price TargetBuy$70.00 -> $72.00View 4/18/2013Lazard Ltd.Boost Price TargetBuy$71.00 -> $77.00View 4/3/2013BarclaysBoost Price TargetOverweight$54.00 -> $70.00View 3/28/2013ZacksReiterated RatingNeutral -> Neutral$63.00View 3/20/2013Jefferies GroupBoost Price TargetBuy$65.00 -> $70.00View 3/20/2013WedbushReiterated RatingNeutral$50.00 -> $53.00View 3/20/2013RBC CapitalBoost Price TargetOutperform$58.00 -> $64.00View 3/20/2013Deutsche BankReiterated RatingHold$45.00 -> $59.00View 3/20/2013Leerink SwannBoost Price TargetOutperform$65.00 -> $72.00View 3/20/2013Piper JaffraySet Price TargetFair Value$65.00 -> $72.00View 3/19/2013S&P Equity ResearchDowngradeBuy -> HoldView 2/25/2013ZacksReiterated RatingNeutral -> Neutral$59.00View 2/22/2013Lazard Ltd.Lower Price TargetBuy$70.00 -> $68.00View 2/22/2013RBC CapitalBoost Price TargetOutperform$55.00 -> $58.00View 2/22/2013Citigroup Inc.Boost Price TargetBuy$61.00 -> $67.00View 2/20/2013WedbushBoost Price Target$46.00 -> $50.00View 2/19/2013William BlairBoost Price TargetOutperform$55.00 -> $65.00View 2/12/2013Canaccord GenuityBoost Price Target$56.00 -> $71.00View 2/1/2013UBS AGBoost Price TargetBuy$53.00 -> $67.00View 1/22/2013Stifel NicolausUpgradeHold -> Buy$67.00View 1/3/2013Janney Montgomery ScottInitiated CoverageBuy$60.00View 1/2/2013Janney Montgomery ScottInitiated CoverageBuyView 1/2/2013JPMorgan Chase & Co.Reiterated RatingOverweight$60.00View 12/27/2012ZacksReiterated RatingNeutral -> Neutral$51.00View 12/7/2012WedbushReiterated RatingNeutral$46.00View 12/4/2012Robert W. BairdReiterated RatingOutperform$54.00View 11/6/2012BarclaysBoost Price TargetOverweight$46.00 -> $54.00View 11/6/2012Summer StreetBoost Price TargetBuy$52.00 -> $69.00View 11/6/2012Brean CapitalDowngradeBuy -> HoldView 11/5/2012Robert W. BairdReiterated RatingOutperform -> Positive$54.00View 11/5/2012Canaccord GenuityBoost Price Target$56.00View 11/5/2012Leerink SwannBoost Price TargetOutperform$44.00 -> $65.00View 11/5/2012Piper JaffrayReiterated RatingOverweight$53.00 -> $53.00View 10/29/2012ZacksReiterated RatingNeutral -> Neutral$41.00View 10/26/2012Robert W. BairdReiterated RatingOutperform$45.00View 10/4/2012ZacksReiterated RatingNeutral -> Neutral$43.00View 10/3/2012Jefferies GroupBoost Price TargetBuy -> Buy$44.00 -> $46.00View 9/28/2012Summer StreetBoost Price TargetBuy$45.00 -> $52.00View 9/27/2012William BlairBoost Price TargetOutperform$46.00 -> $49.00View 9/27/2012Brean CapitalBoost Price TargetBuy$41.00 -> $47.00View 9/24/2012RBC CapitalReiterated RatingOutperformView 9/12/2012William BlairReiterated RatingOutperform$46.00View 9/10/2012Piper JaffrayReiterated RatingOverweight$53.00View 9/7/2012Leerink SwannReiterated RatingOutperform$44.00View 9/5/2012Canaccord GenuityReiterated RatingBuyView 8/27/2012Deutsche BankDowngradeBuy -> Hold$40.00 -> $45.00View 8/24/2012BarclaysInitiated CoverageOverweight$46.00View 8/22/2012Robert W. BairdReiterated RatingOutperformView 8/7/2012Lazard Ltd.Initiated CoverageBuy$57.00View 8/3/2012ZacksReiterated RatingNeutral -> Neutral$39.00View 8/2/2012Canaccord GenuityReiterated RatingBuyView 8/2/2012Robert W. BairdReiterated RatingOutperformView 7/18/2012ZacksReiterated RatingNeutral -> Neutral$44.00View 7/13/2012Piper JaffrayReiterated RatingOverweightView 6/29/2012ThinkEquityInitiated CoverageBuy$44.00View 6/8/2012WedbushReiterated RatingNeutral$35.00View 5/14/2012Citigroup Inc.Boost Price Target$45.00 -> $49.00View 4/30/2012ZacksReiterated RatingNeutral -> Neutral$37.00View 4/27/2012Canaccord GenuityReiterated RatingBuyView 4/12/2012UBS AGInitiated CoverageBuy -> Buy$43.00 -> $43.00View 3/26/2012Canaccord GenuityInitiated CoverageBuy$43.00View 3/19/2012Brean CapitalUpgradeHold -> Buy$41.00View 3/12/2012ZacksUpgradeUnderperform -> Neutral$36.00View (Data available from 3/8/2012 forward) Earnings History for BioMarin Pharmaceutical (NASDAQ:BMRN)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/26/2014Q413($0.35)($0.11)$146.07 million$146.90 millionViewN/AView 10/24/2013Q313($0.30)($0.38)$140.00 million$136.90 millionViewN/AView 7/25/2013Q2 2013($0.29)($0.16)$134.33 million$136.80 millionViewN/AView 4/25/2013Q1 2013($0.30)($0.31)$131.35 million$127.90 millionViewN/AView 2/21/2013Q4 2012($0.22)($0.43)$129.70 million$130.96 millionViewN/AView 10/25/2012($0.20)($0.04)ViewN/AView 8/1/2012($0.19)($0.27)ViewN/AView 4/26/2012($0.15)($0.21)ViewN/AView 2/16/2012($0.10)($0.23)ViewN/AView 10/27/2011($0.10)($0.16)ViewN/AView 7/28/2011($0.09)($0.05)ViewN/AView 4/28/2011($0.10)$0.14ViewN/AView 2/17/2011($0.02)($0.11)ViewN/AView (Data available from 1/1/2011 forward) Dividend History for BioMarin Pharmaceutical (NASDAQ:BMRN)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for BioMarin Pharmaceutical (NASDAQ:BMRN)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare2/3/2014Henry FuchsEVPSell10,000$67.70$677,000.00View 12/24/2013Jean Jacques BienaimeCEOSell10,000$68.71$687,100.00View 12/5/2013Jean Jacques BienaimeCEOSell5,000$69.70$348,500.00View 10/16/2013Jean Jacques BienaimeCEOSell2,000$67.73$135,460.00View 10/10/2013Jean Jacques BienaimeCEOSell3,000$66.76$200,280.00View 9/19/2013Henry FuchsEVPSell10,000$80.19$801,900.00View 9/16/2013Jean Jacques BienaimeCEOSell2,000$73.08$146,160.00View 9/9/2013Robert BaffiEVPSell20,000$73.00$1,460,000.00View 9/5/2013Henry J FuchsEVPSell10,000$70.00$700,000.00View 9/4/2013Daniel K SpiegelmanCFOSell9,000$69.00$621,000.00View 8/15/2013Jean Jacques BienaimeCEOSell1,000$64.36$64,360.00View 7/1/2013Daniel K SpiegelmanCFOSell4,066$59.78$243,065.48View 7/1/2013Henry J FuchsEVPSell10,000$60.00$600,000.00View 6/3/2013Henry J FuchsEVPSell1,098$58.32$64,035.36View 5/23/2013Henry J FuchsEVPSell20,609$66.29$1,366,170.61View 5/22/2013Mark WoodVPSell3,103$67.12$208,273.36View 5/21/2013Jean Jacques BienaimeCEOSell2,000$64.14$128,280.00View 5/16/2013Jean Jacques BienaimeCEOSell12,000$67.90$814,800.00View 5/14/2013Brian MuellerVPSell4,947$70.35$348,021.45View 5/14/2013George Eric DavisSVPSell20,000$70.34$1,406,800.00View 5/14/2013Jean Jacques BienaimeCEOSell15,000$70.17$1,052,550.00View 5/13/2013Jean Jacques BienaimeCEOSell15,800$68.77$1,086,566.00View 5/13/2013Jeffrey Robert AjerSVPSell1,248$69.26$86,436.48View 5/8/2013Jean Jacques BienaimeCEOSell4,000$65.87$263,480.00View 5/2/2013Jean Jacques BienaimeCEOSell3,000$64.99$194,970.00View 4/10/2013Robert BaffiEVPSell20,000$64.00$1,280,000.00View 3/22/2013Mark WoodVPSell3,103$60.21$186,831.63View 3/4/2013George Eric DavisSVPSell4,000$60.18$240,720.00View 2/22/2013Mark WoodVPSell3,103$55.22$171,347.66View 2/4/2013Jean Jacques BienaimeCEOSell2,000$55.77$111,540.00View 12/27/2012Jean Jacques BienaimeCEOSell17,000$48.37$822,290.00View 11/12/2012George Eric DavisSVPSell99,075$48.45$4,800,183.75View 9/4/2012Henry J FuchsEVPSell5,000$37.76$188,800.00View 8/22/2012Mark WoodVPSell2,665$37.93$101,083.45View (Data available from 1/1/2013 forward) About BioMarin Pharmaceutical BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company's product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). It is conducting clinical trials on several product candidates for the treatment of various diseases. They include Vimizim (formerly referred to as GALNS), an enzyme replacement therapy for the treatment of Mucopolysaccharidosis Type IV or Morquio Syndrome Type A (MPS IV A), PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonuria (PKU), and BMN-701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder. On January 7, 2013, the Company acquired Zacharon Pharmaceuticals. Headlines: (3/4) BioMarin Announces Public Offering of Common Stock (3/5) BioMarin Announces Pricing of Public Offering of Common Stock (3/4) BioMarin to Present at the Barclays Global Healthcare Conference in Miami (2/17) BioMarin to Discuss FDA Approval of VIMIZIM(TM) and Provide Preliminary 2013 Results (2/20) BioMarin Receives Positive Opinion From the CHMP in the European Union for VIMIZIM(TM) (elosulfase alfa) for Morquio A ... (2/21) BioMarin Rises on Favorable CHMP Opinion (2/20) The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, Sanofi, Mondelez International, Kraft Foods Group and ... (2/14) BioMarin Announces FDA Approval for VIMIZIM(TM) (elosulfase alfa) for the Treatment of Patients With Morquio A Syndrome Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: BMRN CUSIP: 09061G10 Key Metrics: Previous Close: $79.2850 Day Moving Average: $74.3506200 Day Moving Average: $70.2416 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $11.093BCurrent Quarter EPS Consensus Estimate: $-1.78 EPS Additional Links: View BMRN on Google FinanceView BMRN on Yahoo FinanceView BMRN's Company Profile on ReutersSearch for BioMarin Pharmaceutical Inc. on Google BioMarin Pharmaceutical (NASDAQ:BMRN) Chart for Saturday, March, 8, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.